EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative performance of cobas 4800 HPV Test and Anyplex II HPV HR for high-risk human papillomavirus detection

Luani R Godoy iD, Mariam El-Zein, Elizaveta Padalko, Bo Verberckmoes, Bodine Van Eenooghe, Heleen Vermandere, Sónia Dias, Ana Gama, Bernardo Vega Crespo, Vivian Alejandra Neira, Eduardo L Franco iD, Adhemar Longatto-Filho iD und 1 weitere

Journal of Clinical Microbiology · 2025

DOI: 10.1128/jcm.00200-25 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Clinical Microbiology, 2025. Verfasst von Luani R Godoy und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology, McGill University, Montreal, Québec, Canada. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomaviridae, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Numerous molecular tests are available to detect human papillomavirus (HPV). We compared the analytical performance of cobas and Anyplex for detection of high-risk (HR) carcinogenic HPV genotypes, assessed the composition of HPV types (other than 16 and 18) that influenced cobas performance, and considered the impact of viral load on test performance. We used data from the Early Detection of Cervical Cancer in Hard-to-Reach Populations of Women Through Portable and Point-of-Care HPV Testing project, which involved collection (2019–2022) of cervicovaginal samples from 1,042 women aged 21–74 years in Belgium ( n = 244), Portugal ( n = 309), Brazil ( n = 244), and Ecuador ( n = 245). Samples were tested by cobas (provides individual results for HPV16 and HPV18 and a pooled result for 12 other HR-HPV types) and Anyplex (provides separate results for 14 HR-HPVs). We calculated HPV positivity by each test and compared performance between tests by calculating Cohen’s kappa statistics. Based on 938 samples with complete data from both tests, positivity rates by cobas were 13.4%, 3.6%, 34.3%, and 45.3% for HPV16, HPV18, 12 pooled HR-HPVs, and any HR-HPV, respectively. Corresponding HPV positivity rates by Anyplex were 14.9%, 3.7%, 37.9%, and 50.0% for the same categories, respectively, with high concordance; kappa statistics were 0.90, 0.87, 0.82, and 0.85, respectively. Based on 355 samples that tested positive for at least 1 of the 12 pooled HR-HPVs, most types showed high agreement (80.9%–100.0%) between individual-Anyplex and pooled-cobas HPV results, except for HPV68 (61.3% agreement). Our findings suggest that the two commercial tests may have different performances, depending on the specific HPV types detected, emphasizing the need for continued research on conditions that may affect these tests, especially for less common or less studied HPV types. IMPORTANCE This study compared two commercial tests—cobas and Anyplex—for detecting high-risk HPV types in women undergoing routine cervical cancer screening or referred for colposcopy. Both tests provide separate results for HPV16 and HPV18, but Anyplex also identifies the remaining 12 high-risk HPV types individually, while cobas groups them together. Overall, we found a high level of agreement between the two tests, supporting their use in clinical practice. However, differences in detecting certain HPV types, particularly those that are less common or less studied, emphasize the importance of choosing the right test. As more countries switch to HPV-based cervical cancer screening, using tests that provide detailed results could help improve risk assessment and optimize patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsPapillomaviridaeMolecular Diagnostic TechniquesHumansFemaleMiddle AgedAdultAgedYoung AdultEarly Detection of CancerGenotypeUterine Cervical NeoplasmsSensitivity and SpecificityBrazilEcuadorViral LoadBelgiumPortugalCervix UteriHuman Papillomavirus Viruses

Stichwörter der Autor:innen

Anyplex II HPV HR assaycobas 4800 HPV testhuman papillomavirusperformance

Autor:innen und Institutionen

  • Division of Cancer Epidemiology, McGill University, Montreal, Québec, Canada.
  • Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
  • Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
  • International Centre for Reproductive Health, Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
  • NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center (CHRC), LA-REAL, NOVA University Lisbon, Lisbon, Portugal.
  • Facultad de Ciencias Médicas, Universidad de Cuenca, Cuenca, Ecuador.

ORCID-Profile: Luani R Godoy, Eduardo L Franco, Adhemar Longatto-Filho

Förderung

  • Horizon 2020 Framework Programme
  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Godoy, L. R., El-Zein, M., Padalko, E., Verberckmoes, B., Van Eenooghe, B., Vermandere, H., Dias, S., Gama, A., Vega Crespo, B., Neira, V. A., Franco, E. L., Longatto-Filho, A., & ELEVATE Study Group (2025). Comparative performance of cobas 4800 HPV Test and Anyplex II HPV HR for high-risk human papillomavirus detection. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00200-25

Vancouver

Godoy LR, El-Zein M, Padalko E, Verberckmoes B, Van Eenooghe B, Vermandere H, et al. Comparative performance of cobas 4800 HPV Test and Anyplex II HPV HR for high-risk human papillomavirus detection. Journal of Clinical Microbiology. 2025. doi:10.1128/jcm.00200-25

BibTeX
@article{Godoy2025,
  author = {Godoy, Luani R and El-Zein, Mariam and Padalko, Elizaveta and Verberckmoes, Bo and Van Eenooghe, Bodine and Vermandere, Heleen and Dias, Sónia and Gama, Ana and Vega Crespo, Bernardo and Neira, Vivian Alejandra and Franco, Eduardo L and Longatto-Filho, Adhemar and ELEVATE Study Group, ELEVATE Study Group},
  title = {Comparative performance of cobas 4800 HPV Test and Anyplex II HPV HR for high-risk human papillomavirus detection},
  journal = {Journal of Clinical Microbiology},
  year = {2025},
  doi = {10.1128/jcm.00200-25}
}
Kostenlos starten →